Articles from: OncLive
Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate...
-
Amado J. Zurita-Saavedra, MD, of @MDAndersonNews, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer #pcsm https://t.co/3YwIs53Tto https://t.co/3YwIs53Tto - view on twitter
More coverage:
#pcsm
David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing...
-
David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy. @DCarboneMD @OSUCCC_James #lcsm https://t.co/uoiKWfHHEy - view on twitter
More coverage:
#lcsm
The combination of tislelizumab and gemcitabine/cisplatin continued to demonstrate a greater progression-free survival benefit than chemotherapy alone when used in the frontline treatment of...
-
According to the RATIONALE-309 trial, tislelizumab + gemcitabine/cisplatin continued to demonstrate a greater PFS benefit than chemotherapy alone when used in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer. #oncology https://t.co/fSbwQk1Sak https://t.co/fSbwQk1Sak - view on twitter
More coverage:
#oncology
The safety, tolerability, and preliminary efficacy of the anti-HER2 CAR macrophage therapy, CT-0508, will be investigated in patients with solid tumors and HER2 overexpression,...
-
The safety, tolerability, and preliminary efficacy of the anti-HER2 CAR macrophage therapy, CT-0508, will be investigated in patients with solid tumors and HER2 overexpression, as part of a first-in-human phase 1 study. #oncology #MedTwitter https://t.co/MfeQ7lcVFE - view on twitter
Mashup Score:1
OncLiveTebentafusp Offers Path Forward in the Uveal Melanoma Treatment Landscape - 8 hours
Mashup Score:1
Marlana M. Orloff, MD, overviews how pivotal efficacy and safety data of tebentafusp will improve the treatment paradigm for adult patients with HLA-A*02:01–positive unresectable...
-
The FDA approval of tebentafusp-tebn marks the first available therapy for adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma, a rare subtype of melanoma. @TJUHospital #oncology #medtwitter #melsm https://t.co/A8IOHJG9dW https://t.co/A8IOHJG9dW - view on twitter
Trastuzumab emtansine as a second-line treatment led to shorter median treatment duration and time to treatment failure in patients with HER2-positive metastatic breast cancer...
-
Trastuzumab emtansine as a second-line treatment led to shorter median treatment duration and time to treatment failure in patients with HER2-positive metastatic breast cancer who progressed on pertuzumab and trastuzumab–based regimens. #bcsm https://t.co/KrmMOj3QRr - view on twitter
More coverage:
#bcsm
Michael J. Morris, MD, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate...
-
Michael J. Morris, MD, of @MSKCancerCenter, discusses logistical challenges of utilizing Lutetium 177 PSMA-617 in prostate cancer #pcsm https://t.co/RxxTumlEd7 https://t.co/RxxTumlEd7 - view on twitter
More coverage:
#pcsm
Kelvin P. Lee, MD, discusses the importance of collaboration in precision...
-
WATCH: Kelvin P. Lee, MD, of @IUCancerCenter, discusses the importance of collaboration in precision medicine. #oncology #MedTwitter https://t.co/AL1ouO0PoA https://t.co/AL1ouO0PoA - view on twitter
The FDA has accepted for priority review a supplemental biologics license application for trastuzumab deruxtecan for the treatment of adult patients with unresectable or...
-
The FDA has accepted for priority review a SBLA for trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic NACLCwhose tumors have a HER2 mutation and who have received a prior systemic therapy. #lcsm https://t.co/poNDx3Sk2N https://t.co/poNDx3Sk2N - view on twitter
More coverage:
#lcsm
Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial...
WATCH: @MattGalsky, of @TischCancer, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer. #oncology #MedTwitter https://t.co/EhleZNt3DV https://t.co/EhleZNt3DV - view on twitter